Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel F Alonso

Showing results (71-80 of 92) with videos related to

Pageof 10
Sort By:
Journal of Peptide Science : an Official Publication of the European Peptide Society|March 13, 2012
Sensitivity of tumor cells towards CIGB-300 anticancer peptide relies on its nucleolar localizationYasser Perera, Heydi C Costales, Yakelin Diaz, et al.
Clinical & Developmental Immunology|September 24, 2011
Detection of N-glycolyl GM3 ganglioside in neuroectodermal tumors by immunohistochemistry: an attractive vaccine target for aggressive pediatric cancerAlejandra M Scursoni, Laura Galluzzo, Sandra Camarero, et al.
International Journal of Molecular Sciences|November 9, 2024
Unmasking Neuroendocrine Prostate Cancer with a Machine Learning-Driven Seven-Gene Stemness Signature That Predicts ProgressionAgustina Sabater, Pablo Sanchis, Rocio Seniuk, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|November 10, 2004
Active specific immunotherapy of melanoma with a GM3 ganglioside-based vaccine: a report on safety and immunogenicityMarcelo D Guthmann, Roberto J Bitton, Ariel J L Carnero, et al.
Cancers|October 14, 2022
Preclinical Efficacy and Toxicology Evaluation of RAC1 Inhibitor 1A-116 in Human Glioblastoma ModelsGeorgina A Cardama, Julian Maggio, Lucas Valdez Capuccino, et al.
Animals : an Open Access Journal From MDPI|August 12, 2023
In Silico and In Vitro Evaluation of Bevacizumab Biosimilar MB02 as an Antitumor Agent in Canine Mammary CarcinomaGeorgina A Cardama, Paula L Bucci, Jesús S Lemos, et al.
Cancer Biology & Therapy|January 16, 2007
Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trialElia Neninger, Rosa M Díaz, Ana de la Torre, et al.
JAMA Ophthalmology|October 28, 2016
Minimal Disseminated Disease in Nonmetastatic Retinoblastoma With High-Risk Pathologic Features and Association With Disease-Free SurvivalViviana E Laurent, Ana Vanesa Torbidoni, Claudia Sampor, et al.
BMC Cancer|May 15, 2009
Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignanciesAna M Solares, Agueda Santana, Idania Baladrón, et al.
Investigational New Drugs|March 14, 2020
Administration of the vasopressin analog desmopressin for the management of bleeding in rectal cancer patients: results of a phase I/II trialSoledad Iseas, Enrique L Roca, Juan M O'Connor, et al.
Pageof 10

Showing results (71-80 of 92) with videos related to

Sort By:
Pageof 10
Journal of Peptide Science : an Official Publication of the European Peptide Society|March 13, 2012
Sensitivity of tumor cells towards CIGB-300 anticancer peptide relies on its nucleolar localizationYasser Perera, Heydi C Costales, Yakelin Diaz, et al.
Clinical & Developmental Immunology|September 24, 2011
Detection of N-glycolyl GM3 ganglioside in neuroectodermal tumors by immunohistochemistry: an attractive vaccine target for aggressive pediatric cancerAlejandra M Scursoni, Laura Galluzzo, Sandra Camarero, et al.
International Journal of Molecular Sciences|November 9, 2024
Unmasking Neuroendocrine Prostate Cancer with a Machine Learning-Driven Seven-Gene Stemness Signature That Predicts ProgressionAgustina Sabater, Pablo Sanchis, Rocio Seniuk, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|November 10, 2004
Active specific immunotherapy of melanoma with a GM3 ganglioside-based vaccine: a report on safety and immunogenicityMarcelo D Guthmann, Roberto J Bitton, Ariel J L Carnero, et al.
Cancers|October 14, 2022
Preclinical Efficacy and Toxicology Evaluation of RAC1 Inhibitor 1A-116 in Human Glioblastoma ModelsGeorgina A Cardama, Julian Maggio, Lucas Valdez Capuccino, et al.
Animals : an Open Access Journal From MDPI|August 12, 2023
In Silico and In Vitro Evaluation of Bevacizumab Biosimilar MB02 as an Antitumor Agent in Canine Mammary CarcinomaGeorgina A Cardama, Paula L Bucci, Jesús S Lemos, et al.
Cancer Biology & Therapy|January 16, 2007
Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trialElia Neninger, Rosa M Díaz, Ana de la Torre, et al.
JAMA Ophthalmology|October 28, 2016
Minimal Disseminated Disease in Nonmetastatic Retinoblastoma With High-Risk Pathologic Features and Association With Disease-Free SurvivalViviana E Laurent, Ana Vanesa Torbidoni, Claudia Sampor, et al.
BMC Cancer|May 15, 2009
Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignanciesAna M Solares, Agueda Santana, Idania Baladrón, et al.
Investigational New Drugs|March 14, 2020
Administration of the vasopressin analog desmopressin for the management of bleeding in rectal cancer patients: results of a phase I/II trialSoledad Iseas, Enrique L Roca, Juan M O'Connor, et al.
Pageof 10